Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula

Get In Touch

Quick Email
info.help@gmail.com
  • Home |
  • Astellas unearths Dyno muscle disorder AAV capsid with $15M option agreement

Astellas unearths Dyno muscle disorder AAV capsid with $15M option agreement

  • April 7, 2026

Following a research collaboration established in 2021, Astellas Pharma has reached an agreement to license a Dyno Therapeutics gene therapy vehicle—an adeno-associated virus (AAV) capsid engineered for therapeutic delivery to skeletal muscle.

Leave A Comment

Fields (*) Mark are Required